Study of Silodosin to Treat Urinary Symptoms in Women With Multiple Sclerosis

What this Trial Is About

Researchers are investigating whether silodosin can help treat lower urinary tract symptoms LUTS in female patients with multiple sclerosis MS. The study aims to find out if silodosin improves symptoms based on questionnaires and changes uroflowmetry measurements compared to a placebo. This randomized controlled trial is sponsored by Atlantic Health System and focuses on female patients with moderate to severe LUTS related to MS. Participants will be randomly assigned to take either silodosin 8 mg or a placebo capsule once daily for 8 weeks. The study uses a quadruple-blind design, meaning neither participants nor researchers know which treatment is given. Before starting the medication and after 8 weeks, patients will visit the clinic for questionnaires and tests to assess urinary symptoms and voiding function. During the study, participants will complete symptom questionnaires including the American Urological Association Symptom Score AUASS, Urinary Distress Inventory, and Overactive Bladder Symptom Score. Uroflowmetry tests will measure urine flow patterns, volume, and residual urine after voiding. Researchers will monitor medication adherence and any side effects throughout the treatment period. The total participation involves the initial visit, 8 weeks of daily medication, and a final evaluation visit.

Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis